AR107310A1 - Inhibidores de tetrahidrocarbazol de receptores sirt1 - Google Patents
Inhibidores de tetrahidrocarbazol de receptores sirt1Info
- Publication number
- AR107310A1 AR107310A1 ARP170100034A ARP170100034A AR107310A1 AR 107310 A1 AR107310 A1 AR 107310A1 AR P170100034 A ARP170100034 A AR P170100034A AR P170100034 A ARP170100034 A AR P170100034A AR 107310 A1 AR107310 A1 AR 107310A1
- Authority
- AR
- Argentina
- Prior art keywords
- sirt1
- inhibitors
- deuterium
- tetrahydrocarbazol
- receptors
- Prior art date
Links
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 title abstract 3
- 102000000344 Sirtuin 1 Human genes 0.000 title abstract 3
- 108010041191 Sirtuin 1 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 5
- 229910052805 deuterium Inorganic materials 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen compuestos tetrahidrocarbazol sustituido con deuterio como inhibidores de sirtuina 1 (SIRT1). También se describen composiciones farmacéuticas que comprenden los compuestos tetrahidrocarbazol sustituido con deuterio y métodos de uso de los mismos. Reivindicación 1: Un compuesto que tiene la estructura de la fórmula (1) o una sal, profármaco, o solvato del mismo, en donde R¹ - R⁷ son, independientemente, hidrógeno o deuterio; por lo menos uno de R¹ - R⁷ es deuterio; y por lo menos uno de R¹ - R⁷ tiene un enriquecimiento de deuterio no menor del 10%.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275444P | 2016-01-06 | 2016-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107310A1 true AR107310A1 (es) | 2018-04-18 |
Family
ID=57868399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100034A AR107310A1 (es) | 2016-01-06 | 2017-01-06 | Inhibidores de tetrahidrocarbazol de receptores sirt1 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9884819B2 (es) |
| EP (1) | EP3400212A1 (es) |
| AR (1) | AR107310A1 (es) |
| TW (1) | TW201726617A (es) |
| WO (1) | WO2017120409A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3897634A4 (en) * | 2018-12-18 | 2022-09-21 | The Board of Trustees of the Leland Stanford Junior University | COMPOUNDS FOR THE REDUCTION OF THE DELETIVE ACTIVITY OF GENE CONTAINING EXTENDED NUCLEOTIDE REPETITION |
| WO2022192645A1 (en) * | 2021-03-12 | 2022-09-15 | The General Hospital Corporation | Compounds for brain imaging |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005208934A1 (en) | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc | Treating a viral disorder |
| WO2007047604A2 (en) * | 2005-10-18 | 2007-04-26 | Elixir Pharmaceuticals, Inc. | Sirt1 inhibition |
| EP4502609A3 (en) | 2012-01-26 | 2025-04-09 | Vanda Pharmaceuticals Inc. | Determining a circadian rhythm |
-
2017
- 2017-01-06 US US15/400,144 patent/US9884819B2/en active Active
- 2017-01-06 TW TW106100428A patent/TW201726617A/zh unknown
- 2017-01-06 AR ARP170100034A patent/AR107310A1/es unknown
- 2017-01-06 EP EP17701225.9A patent/EP3400212A1/en not_active Withdrawn
- 2017-01-06 WO PCT/US2017/012442 patent/WO2017120409A1/en not_active Ceased
-
2018
- 2018-01-03 US US15/861,152 patent/US20180127366A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9884819B2 (en) | 2018-02-06 |
| WO2017120409A1 (en) | 2017-07-13 |
| TW201726617A (zh) | 2017-08-01 |
| US20180127366A1 (en) | 2018-05-10 |
| EP3400212A1 (en) | 2018-11-14 |
| US20170190664A1 (en) | 2017-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| NI201800133A (es) | Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CL2022001529A1 (es) | Nuevos derivados de metilquinazolinona | |
| DOP2018000270A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CL2018003504A1 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos. | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| MX2018003432A (es) | Compuestos heterociclicos y usos de los mismos. | |
| CU20220005A7 (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX381707B (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| CU20170105A7 (es) | Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos | |
| SV2016005180A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| CL2016001287A1 (es) | Benzamidas sustituidas y procedimiento para su uso | |
| AR104174A1 (es) | Oxadiazoles sustituidos con deuterio | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| CR20180072A (es) | Nuevos compuestos biciclicos como inhibidores de atx | |
| CR20180143A (es) | Nuevos compuestos biciclicos como inhibidores duales de atx/ca | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| AR104731A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| CO2022006965A2 (es) | Inhibidores de egfr | |
| JOP20200030A1 (ar) | مركب خماسي الحلقة | |
| SV2018005701A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| MX2019010330A (es) | Formulaciones con mejora de la estabilidad. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |